The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

por Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, Yoshihiko Taniguchi, Kazumi Nishino, Shinji Atagi, Tomonori Hirashima, Fumio Imamura, Toru Kumagai, Hidekazu Suzuki
Publicado 2021

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case R...

por Kei Kunimasa, MD, PhD, Jiro Okami, MD, PhD, Satoshi Takenaka, MD, PhD, Keiichiro Honma, MD, PhD, Yoji Kukita, PhD, Shigenori Nagata, MD, PhD, Takahisa Kawamura, MD, PhD, Takako Inoue, MD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Hideaki Tahara, MD, PhD, Toru Kumagai, MD, PhD
Publicado 2021